{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T22:03:40Z","timestamp":1775253820388,"version":"3.50.1"},"reference-count":123,"publisher":"Bentham Science Publishers Ltd.","issue":"10","funder":[{"DOI":"10.13039\/501100001411","name":"National Institute of Cholera and Enteric Diseases, ICMR Project","doi-asserted-by":"publisher","award":["04\/Phage Therapy\/2021-22"],"award-info":[{"award-number":["04\/Phage Therapy\/2021-22"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPB"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Bacterial infections continue to jeopardize human and animal health, impacting millions\nof lives by causing significant deaths every year. The use of antibiotics remains the primary choice\nof therapy and has only been partly successful in reducing the disease burden due to the evolving\nnature of resistant microbes. Widespread and inappropriate use of antibiotics resulted in the development\nof antibiotic-resistant microbial species provoking substantial economic burdens. The most\npromising way to resolve the issue of antibiotic resistance is the use of bacterial viruses called bacteriophages\nto treat microbial infections. Earlier reports on experimental bacteriophage therapy\nshowed successful patient outcomes, and many clinical trials of such clinical bacteriophages have\nalready been investigated in many western countries. In this review, we are focusing on the advantages\nas well as drawbacks of bacteriophage therapy to use it as an alternative to antibiotics for microbial\ninfections, together with its current success status. There is also a need to extensively study\nthe past, present, and future outlook of phage therapy in comparison to presently available antimicrobial\nagents and especially immunological response by the host after phage administration. Our\naim is to highlight the fast-promoting field of bacteriophage therapy and provocations that lie ahead\nas the world is gradually moving aside from complete dependence on antimicrobial agents.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389201024666221207114047","type":"journal-article","created":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T05:34:21Z","timestamp":1670823261000},"page":"1277-1290","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Phage Therapy as a Protective Tool Against Pathogenic Bacteria: How Far\nWe Are?"],"prefix":"10.2174","volume":"24","author":[{"given":"Alok Kumar","family":"Chakrabarti","sequence":"first","affiliation":[{"name":"Division of Virology, Vibrio Phage Reference Laboratory, National Institute of Cholera and Enteric Diseases, Kolkata,\nWest Bengal, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kushagri","family":"Singh","sequence":"additional","affiliation":[{"name":"Division of Virology, Vibrio Phage Reference Laboratory, National Institute of Cholera and Enteric Diseases, Kolkata,\nWest Bengal, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asim","family":"Biswas","sequence":"additional","affiliation":[{"name":"School of Veterinary Medicine, Pathobiological Sciences, Influenza Research Institute (IRI),\nUniversity of Wisconsin-Madison, Madison, Wisconsin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanta","family":"Dutta","sequence":"additional","affiliation":[{"name":"Division of Virology, Vibrio Phage Reference Laboratory, National Institute of Cholera and Enteric Diseases, Kolkata,\nWest Bengal, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"614","volume":"62","author":"D\u2019Herelle F.","year":"1927","unstructured":"D\u2019Herelle F.; Malone R.H.; A preliminary report of work carried out by the cholera bacteriophage enquiry. Ind Med Gaz 1927,62(11),614-616","journal-title":"Ind Med Gaz"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1071\/MA17029","volume":"38","author":"Aminov R.","year":"2017","unstructured":"Aminov R.; Caplin J.; Chanishvili N.; Coffey A.; Cooper I.; De Vos D.; Do\u0161ka\u0159 J.; Friman V.P.; Kurtb\u00f6ke \u0130.; Pantucek R.; Pirnay J.P.; Resch G.; Rohde C.; Sybesma W.; Wittmann J.; Application of bacteriophages. Microbiol Aust 2017,38(2),63-66","journal-title":"Microbiol Aust"},{"key":"ref=3","first-page":"226","volume":"10","author":"Fleming A.","year":"1929","unstructured":"Fleming A.; On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae. Br J Exp Pathol 1929,10(3),226","journal-title":"Br J Exp Pathol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"130","DOI":"10.4161\/bact.20757","volume":"2","author":"Summers W.C.","year":"2012","unstructured":"Summers W.C.; The strange history of phage therapy. Bacteriophage 2012,2(2),130-133","journal-title":"Bacteriophage"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"e6225","DOI":"10.7717\/peerj.6225","volume":"7","author":"Tang S.S.","year":"2019","unstructured":"Tang S.S.; Biswas S.K.; Tan W.S.; Saha A.K.; Leo B.F.; Efficacy and potential of phage therapy against multidrug resistant Shigella spp. PeerJ 2019,7,e6225","journal-title":"PeerJ"},{"key":"ref=6","first-page":"HS-3","volume":"33","author":"Clarke A.","year":"2008","unstructured":"Clarke A.; Stein C.R.; Townsend M.L.; Drug-drug interactions with HIV antiretroviral therapy. US Pharm 2008,33(4),HS-3-HS-21","journal-title":"US Pharm"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1099\/ijs.0.021782-0","volume":"61","author":"Br\u00e4uer S.L.","year":"2011","unstructured":"Br\u00e4uer S.L.; Cadillo-Quiroz H.; Ward R.J.; Yavitt J.B.; Zinder S.H.; Methanoregula boonei gen. nov., sp. nov., an acidiphilic methano-gen isolated from an acidic peat bog. Int J Syst Evol Microbiol 2011,61(1),45-52","journal-title":"Int J Syst Evol Microbiol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","volume":"19","author":"Cassini A.","year":"2019","unstructured":"Cassini A.; H\u00f6gberg L.D.; Plachouras D.; Quattrocchi A.; Hoxha A.; Simonsen G.S.; Colomb-Cotinat M.; Kretzschmar M.E.; Devleesschauwer B.; Cecchini M.; Ouakrim D.A.; Oliveira T.C.; Struelens M.J.; Suetens C.; Monnet D.L.; Strauss R.; Mertens K.; Struyf T.; Catry B.; Latour K.; Ivanov I.N.; Dobreva E.G.; Tambic Andra\u0161evic A.; Soprek S.; Budimir A.; Paphitou N.; \u017demlickov\u00e1 H.; Schytte Olsen S.; Wolff S\u00f6nksen U.; M\u00e4rtin P.; Ivanova M.; Lyytik\u00e4inen O.; Jalava J.; Coignard B.; Eckmanns T.; Abu Sin M.; Haller S.; Daikos G.L.; Gikas A.; Tsiodras S.; Kontopidou F.; T\u00f3th \u00c1.; Hajdu \u00c1.; Gu\u00f3laugsson \u00d3.; Kristinsson K.G.; Murchan S.; Burns K.; Pezzotti P.; Gagliotti C.; Dumpis U.; Liuimiene A.; Perrin M.; Borg M.A.; de Greeff S.C.; Monen J.C.M.; Koek M.B.G.; El-str\u00f8m P.; Zabicka D.; Deptula A.; Hryniewicz W.; Cani\u00e7a M.; Nogueira P.J.; Fernandes P.A.; Manageiro V.; Popescu G.A.; Serban R.I.; Schr\u00e9terov\u00e1 E.; Litvov\u00e1 S.; \u0160tefkovicov\u00e1 M.; Kolman J.; Klavs I.; Koro\u0161ec A.; Aracil B.; Asensio A.; P\u00e9rez-V\u00e1zquez M.; Bill-str\u00f6m H.; Larsson S.; Reilly J.S.; Johnson A.; Hopkins S.; Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: A population-level modelling analysis. Lancet Infect Dis 2019,19(1),56-66","journal-title":"Lancet Infect Dis"},{"key":"ref=9","year":"2014","unstructured":"Antimicrobial resistance global report on surveillance: 2014 summary World Health Organization2014","journal-title":"Antimicrobial resistance global report on surveillance: 2014 summary"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1097\/CCM.0000000000004371","volume":"48","author":"Kadri S.S.","year":"2020","unstructured":"Kadri S.S.; Key takeaways from the US CDC\u2019s 2019 antibiotic resistance threats report for frontline providers. Crit Care Med 2020,48(7),939-945","journal-title":"Crit Care Med"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/j.1751-7915.2011.00259.x","volume":"4","author":"Kvachadze L.","year":"2011","unstructured":"Kvachadze L.; Balarjishvili N.; Meskhi T.; Tevdoradze E.; Skhirtladze N.; Pataridze T.; Adamia R.; Topuria T.; Kutter E.; Rohde C.; Kutateladze M.; Evaluation of lytic activity of staphylococcal bacteriophage Sb-1 against freshly isolated clinical pathogens. Microb Biotechnol 2011,4(5),643-650","journal-title":"Microb Biotechnol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"570","DOI":"10.3390\/microorganisms7110570","volume":"7","author":"Wei S.","year":"2019","unstructured":"Wei S.; Chelliah R.; Rubab M.; Oh D.H.; Uddin M.J.; Ahn J.; Bacteriophages as potential tools for detection and control of Salmonella spp. in food systems. Microorganisms 2019,7(11),570","journal-title":"Microorganisms"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1146\/annurev-food-030212-182554","volume":"5","author":"Salonen A.","year":"2014","unstructured":"Salonen A.; de Vos W.M.; Impact of diet on human intestinal microbiota and health. Annu Rev Food Sci Technol 2014,5(1),239-262","journal-title":"Annu Rev Food Sci Technol"},{"key":"ref=14","first-page":"569","volume":"35","author":"Slopek S.","year":"1987","unstructured":"Slopek S.; Weber-Dabrowska B.; Dabrowski M.; Kucharewicz-Krukowska A.; Results of bacteriophage treatment of suppurative bacteri-al infections in the years 1981-1986. Arch Immunol Ther Exp 1987,35(5),569-583","journal-title":"Arch Immunol Ther Exp"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2147\/IDR.S234353","volume":"13","author":"Taati Moghadam M.","year":"2020","unstructured":"Taati Moghadam M.; Amirmozafari N.; Shariati A.; Hallajzadeh M.; Mirkalantari S.; Khoshbayan A.; Masjedian Jazi F.; How phages overcome the challenges of drug resistant bacteria in clinical infections. Infect Drug Resist 2020,13,45-61","journal-title":"Infect Drug Resist"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"e00066","DOI":"10.1128\/CMR.00066-18","volume":"32","author":"Gordillo Altamirano F.L.","year":"2019","unstructured":"Gordillo Altamirano F.L.; Barr J.J.; Phage therapy in the postantibiotic era. Clin Microbiol Rev 2019,32(2),e00066-e18","journal-title":"Clin Microbiol Rev"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1128\/AAC.45.3.649-659.2001","volume":"45","author":"Sulakvelidze A.","year":"2001","unstructured":"Sulakvelidze A.; Alavidze Z.; Morris J.G.; Bacteriophage therapy. Antimicrob Agents Chemother 2001,45(3),649-659","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3390\/antibiotics7020035","volume":"7","author":"Sybesma W.","year":"2018","unstructured":"Sybesma W.; Rohde C.; Bardy P.; Pirnay J.P.; Cooper I.; Caplin J.; Chanishvili N.; Coffey A.; De Vos D.; Scholz A.; McCallin S.; P\u00fcschner H.; Pantucek R.; Aminov R.; Do\u0161ka\u0159 J.; Kurtb\u04e7ke D.; Silk route to the acceptance and re-implementation of bacteriophage therapy-part II. Antibiotics 2018,7(2),35","journal-title":"Antibiotics"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/978-3-030-26736-0_3","author":"McCallin S.","year":"2019","unstructured":"McCallin S.; Oechslin F.;  In: Bacterial resistance to phage and its impact on clinical therapy InPhage Therapy: A Practical Approach 2019,59-88","journal-title":"In: Bacterial resistance to phage and its impact on clinical therapy InPhage Therapy: A Practical Approach"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3389\/fcimb.2018.00376","volume":"8","author":"Furfaro L.L.","year":"2018","unstructured":"Furfaro L.L.; Payne M.S.; Chang B.J.; Bacteriophage therapy: Clinical trials and regulatory hurdles. Front Cell Infect Microbiol 2018,8,376","journal-title":"Front Cell Infect Microbiol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1089\/sur.2018.184","volume":"19","author":"Rohde C.","year":"2018","unstructured":"Rohde C.; Wittmann J.; Kutter E.; Bacteriophages: A therapy concept against multi-drug-resistant bacteria. Surg Infect 2018,19(8),737-744","journal-title":"Surg Infect"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.12968\/jowc.2016.25.7.S27","volume":"25","author":"Fish R","year":"2016","unstructured":"Fish R; Kutter E; Wheat G; Blasdel B; Kutateladze M; Kuhl S; Bacteriophage treatment of intransigent diabetic toe ulcers: A case series. J Wound Care 2016,25(Sup7),S27-S33","journal-title":"J Wound Care"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"572096","DOI":"10.3389\/fcimb.2020.572096","volume":"10","author":"Ramamurthy T.","year":"2020","unstructured":"Ramamurthy T.; Nandy R.K.; Mukhopadhyay A.K.; Dutta S.; Mutreja A.; Okamoto K.; Miyoshi S.I.; Nair G.B.; Ghosh A.; Virulence regulation and innate host response in the pathogenicity of Vibrio cholerae. Front Cell Infect Microbiol 2020,10,572096","journal-title":"Front Cell Infect Microbiol"},{"key":"ref=24","first-page":"11","volume":"5","author":"Henry B.A.","year":"2019","unstructured":"Henry B.A.; A case series of emergency investigational new drug applications for bacteriophages treating recalcitrant multi-drug resistant bacterial infections: confirmed safety and a signal of efficacy. J Intensive Critical Care 2019,5(2),11","journal-title":"J Intensive Critical Care"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3390\/antibiotics9030135","volume":"9","author":"Nikolich M.P.","year":"2020","unstructured":"Nikolich M.P.; Filippov A.A.; Bacteriophage therapy: Developments and directions. Antibiotics 2020,9(3),135","journal-title":"Antibiotics"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.36348\/sb.2021.v07i03.003","volume":"7","author":"Raza A.","year":"2021","unstructured":"Raza A.; jamil, M.; Tahir Aleem, M.; Aamir Aslam, M.; Muhammad Ali, H.; khan, S.; Kareem, N.; Asghar, T.; Gul, K.; Nadeem, H.; Ab-bass, J.; Khan, S. Bacteriophage therapy: Recent development and applications. Scholars Bulletin 2021,7(3),27-37","journal-title":"Scholars Bulletin"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.4049\/jimmunol.1701745","volume":"200","author":"Krut O.","year":"2018","unstructured":"Krut O.; Bekeredjian-Ding I.; Contribution of the immune response to phage therapy. J Immunol 2018,200(9),3037-3044","journal-title":"J Immunol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"14802","DOI":"10.1038\/srep14802","volume":"5","author":"Hodyra-Stefaniak K.","year":"2015","unstructured":"Hodyra-Stefaniak K.; Miernikiewicz P.; Drapa\u0142a J.; Drab M.; Jo\u0144czyk-Matysiak E.; Lecion D.; Ka\u017amierczak Z.; Beta W.; Majewska J.; Harhala M.; Bubak B.; K\u0142opot A.; G\u00f3rski A.; D\u0105browska K.; Mammalian host-versus-phage immune response determines phage fate in vivo. Sci Rep 2015,5(1),14802","journal-title":"Sci Rep"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"e1096995","DOI":"10.1080\/21597081.2015.1096995","volume":"6","author":"Mapes A.C.","year":"2016","unstructured":"Mapes A.C.; Trautner B.W.; Liao K.S.; Ramig R.F.; Development of expanded host range phage active on biofilms of multi-drug re-sistant Pseudomonas aeruginosa. Bacteriophage 2016,6(1),e1096995","journal-title":"Bacteriophage"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1006\/anae.1999.0192","volume":"5","author":"Ramesh V.","year":"1999","unstructured":"Ramesh V.; Fralick J.A.; Rolfe R.D.; Prevention of Clostridium difficile -induced ileocecitis with bacteriophage. Anaerobe 1999,5(2),69-78","journal-title":"Anaerobe"},{"key":"ref=31","first-page":"95","volume":"73","author":"Soothill J.S.","year":"1992","unstructured":"Soothill J.S.; Morton D.B.; Ahmad A.; The HID50 (hypothermia-inducing dose 50): An alternative to the LD50 for measurement of bac-terial virulence. Int J Exp Pathol 1992,73(1),95-98","journal-title":"Int J Exp Pathol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"26717","DOI":"10.1038\/srep26717","volume":"6","author":"Chan B.K.","year":"2016","unstructured":"Chan B.K.; Sistrom M.; Wertz J.E.; Kortright K.E.; Narayan D.; Turner P.E.; Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa. Sci Rep 2016,6(1),26717","journal-title":"Sci Rep"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"162","DOI":"10.4292\/wjgpt.v8.i3.162","volume":"8","author":"Lin D.M.","year":"2017","unstructured":"Lin D.M.; Koskella B.; Lin H.C.; Phage therapy: An alternative to antibiotics in the age of multi-drug resistance. World J Gastrointest Pharmacol Ther 2017,8(3),162-173","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1111\/j.1462-2920.2006.01054.x","volume":"8","author":"Cabello F.C.","year":"2006","unstructured":"Cabello F.C.; Heavy use of prophylactic antibiotics in aquaculture: A growing problem for human and animal health and for the environ-ment. Environ Microbiol 2006,8(7),1137-1144","journal-title":"Environ Microbiol"},{"key":"ref=35","first-page":"449","volume":"24","author":"Suthienkul O.","year":"1993","unstructured":"Suthienkul O.; Bacteriophage typing of Vibrio fluvialis. Southeast Asian J Trop Med Public Health 1993,24(3),449-454","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/j.1365-2672.2004.02362.x","volume":"97","author":"Payne M.","year":"2004","unstructured":"Payne M.; Oakey J.; Owens L.; The ability of two different Vibrio spp. bacteriophages to infect Vibrio harveyi, Vibrio cholerae and Vibrio mimicus. J Appl Microbiol 2004,97(4),663-672","journal-title":"J Appl Microbiol"},{"key":"ref=37","first-page":"329","volume":"37","author":"Scarano C.","year":"2014","unstructured":"Scarano C.; Spanu C.; Ziino G.; Pedonese F.; Dalmasso A.; Spanu V.; Virdis S.; De Santis E.P.; Antibiotic resistance of Vibrio species isolated from Sparus aurata reared in Italian mariculture. New Microbiol 2014,37(3),329-337","journal-title":"New Microbiol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3354\/meps120089","volume":"120","author":"Kellogg C.A.","year":"1995","unstructured":"Kellogg C.A.; Rose J.B.; Jiang S.C.; Thurmond J.M.; Paul J.H.; Genetic diversity of related vibriophages isolated from marine environ-ments around Florida and Hawaii, USA. Mar Ecol Prog Ser 1995,120,89-98","journal-title":"Mar Ecol Prog Ser"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1021\/acsinfecdis.1c00366","volume":"7","author":"Nogueira C.L.","year":"2021","unstructured":"Nogueira C.L.; Pires D.P.; Monteiro R.; Santos S.B.; Carvalho C.M.; Exploitation of a Klebsiella bacteriophage receptor-binding protein as a superior biorecognition molecule. ACS Infect Dis 2021,7(11),3077-3087","journal-title":"ACS Infect Dis"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41591-019-0437-z","volume":"25","author":"Dedrick R.M.","year":"2019","unstructured":"Dedrick R.M.; Guerrero-Bustamante C.A.; Garlena R.A.; Russell D.A.; Ford K.; Harris K.; Gilmour K.C.; Soothill J.; Jacobs-Sera D.; Schooley R.T.; Hatfull G.F.; Spencer H.; Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Myco-bacterium abscessus. Nat Med 2019,25(5),730-733","journal-title":"Nat Med"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1128\/AEM.05741-11","volume":"78","author":"Edgar R.","year":"2012","unstructured":"Edgar R.; Friedman N.; Molshanski-Mor S.; Qimron U.; Reversing bacterial resistance to antibiotics by phage-mediated delivery of dom-inant sensitive genes. Appl Environ Microbiol 2012,78(3),744-751","journal-title":"Appl Environ Microbiol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.resmic.2012.08.008","volume":"164","author":"Knezevic P.","year":"2013","unstructured":"Knezevic P.; Curcin S.; Aleksic V.; Petrusic M.; Vlaski L.; Phage-antibiotic synergism: a possible approach to combatting Pseudomonas aeruginosa. Res Microbiol 2013,164(1),55-60","journal-title":"Res Microbiol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3390\/microorganisms9010152","volume":"9","author":"Davis C.M.","year":"2021","unstructured":"Davis C.M.; McCutcheon J.G.; Dennis J.J.; Aztreonam lysine increases the activity of phages E79 and phiKZ against Pseudomonas aeru-ginosa PA01. Microorganisms 2021,9(1),152","journal-title":"Microorganisms"},{"key":"ref=44","author":"Chan W.","year":"2016","unstructured":"Chan W.; Zhang Y.; Le Q.; Jaitly N.;  Latent sequence decompositions 2016","journal-title":"Latent sequence decompositions"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"279","DOI":"10.4172\/1747-0862.1000050","volume":"6","author":"Parracho H.M.R.T.","year":"2012","unstructured":"Parracho H.M.R.T.; Burrowes B.H.; Enright M.C.; McConville M.L.; Harper D.R.; The role of regulated clinical trials in the development of bacteriophage therapeutics. J Mol Genet Med 2012,6(1),279-286","journal-title":"J Mol Genet Med"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"769","DOI":"10.2217\/fmb.13.47","volume":"8","author":"Chan B.K.","year":"2013","unstructured":"Chan B.K.; Abedon S.T.; Loc-Carrillo C.; Phage cocktails and the future of phage therapy. Future Microbiol 2013,8(6),769-783","journal-title":"Future Microbiol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/B978-0-12-394438-2.00003-7","volume":"83","author":"Mi\u0119dzybrodzki R.","year":"2012","unstructured":"Mi\u0119dzybrodzki R.; Borysowski J.; Weber-D\u0105browska B.; Fortuna W.; Letkiewicz S.; Szufnarowski K.; Pawe\u0142czyk Z.; Rog\u00f3\u017c P.; K\u0142ak M.; Wojtasik E.; G\u00f3rski A.; Clinical aspects of phage therapy. Adv Virus Res 2012,83,73-121","journal-title":"Adv Virus Res"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1139\/f05-247","volume":"63","author":"Grafton R.Q.","year":"2006","unstructured":"Grafton R.Q.; Arnason R.; Bj\u00f8rndal T.; Campbell D.; Campbell H.F.; Clark C.W.; Connor R.; Dupont D.P.; Hannesson R.; Hilborn R.; Kirkley J.E.; Kompas T.; Lane D.E.; Munro G.R.; Pascoe S.; Squires D.; Steinshamn S.I.; Turris B.R.; Weninger Q.; Incentive-based approaches to sustainable fisheries. Can J Fish Aquat Sci 2006,63(3),699-710","journal-title":"Can J Fish Aquat Sci"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3390\/antibiotics3030270","volume":"3","author":"Harper D.","year":"2014","unstructured":"Harper D.; Parracho H.; Walker J.; Sharp R.; Hughes G.; Werth\u00e9n M.; Lehman S.; Morales S.; Bacteriophages and Biofilms. Antibiotics 2014,3(3),270-284","journal-title":"Antibiotics"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1099\/mic.0.27849-0","volume":"151","author":"Br\u00fcssow H.","year":"2005","unstructured":"Br\u00fcssow H.; Phage therapy: the Escherichia coli experience. Microbiology 2005,151(7),2133-2140","journal-title":"Microbiology"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"905","DOI":"10.2217\/fmb-2017-0049","volume":"12","author":"G\u00f3rski A.","year":"2017","unstructured":"G\u00f3rski A.; D\u0105browska K.; Mi\u0119dzybrodzki R.; Weber-D\u0105browska B.; \u0141usiak-Szelachowska M.; Jo\u0144czyk-Matysiak E.; Borysowski J.; Phages and immunomodulation. Future Microbiol 2017,12(10),905-914","journal-title":"Future Microbiol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1128\/AEM.00785-09","volume":"76","author":"Wall S.K.","year":"2010","unstructured":"Wall S.K.; Zhang J.; Rostagno M.H.; Ebner P.D.; Phage therapy to reduce preprocessing Salmonella infections in market-weight swine. Appl Environ Microbiol 2010,76(1),48-53","journal-title":"Appl Environ Microbiol"},{"key":"ref=53","first-page":"1560","volume":"100","author":"Morison J.","year":"1933","unstructured":"Morison J.; Bacteriophage in the treatment and prevention of cholera. JAMA 1933,100(19),1560-1561","journal-title":"JAMA"},{"key":"ref=54","first-page":"361","volume":"28","author":"Sayamov R.M.","year":"1963","unstructured":"Sayamov R.M.; Treatment and prophylaxis of cholera with bacteriophage. Bull World Health Organ 1963,28(3),361-367","journal-title":"Bull World Health Organ"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"14187","DOI":"10.1038\/ncomms14187","volume":"8","author":"Yen M.","year":"2017","unstructured":"Yen M.; Cairns L.S.; Camilli A.; A cocktail of three virulent bacteriophages prevents Vibrio cholerae infection in animal models. Nat Commun 2017,8(1),14187","journal-title":"Nat Commun"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1111\/j.1462-2920.2006.01006.x","volume":"8","author":"Comeau A.M.","year":"2006","unstructured":"Comeau A.M.; Chan A.M.; Suttle C.A.; Genetic richness of vibriophages isolated in a coastal environment. Environ Microbiol 2006,8(7),1164-1176","journal-title":"Environ Microbiol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1093\/infdis\/jiu059","volume":"210","author":"Jun J.W.","year":"2014","unstructured":"Jun J.W.; Shin T.H.; Kim J.H.; Shin S.P.; Han J.E.; Heo G.J.; De Zoysa M.; Shin G.W.; Chai J.Y.; Park S.C.; Bacteriophage therapy of a Vibrio parahaemolyticus infection caused by a multiple-antibiotic-resistant O3:K6 pandemic clinical strain. J Infect Dis 2014,210(1),72-78","journal-title":"J Infect Dis"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ejbt.2017.10.012","volume":"31","author":"Plaza N.","year":"2018","unstructured":"Plaza N.; Castillo D.; P\u00e9rez-Reytor D.; Higuera G.; Garc\u00eda K.; Bast\u00edas R.; Bacteriophages in the control of pathogenic vibrios. Electron J Biotechnol 2018,31,24-33","journal-title":"Electron J Biotechnol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s40168-015-0131-4","volume":"3","author":"Castro-Mej\u00eda J.L.","year":"2015","unstructured":"Castro-Mej\u00eda J.L.; Muhammed M.K.; Kot W.; Neve H.; Franz C.M.A.P.; Hansen L.H.; Vogensen F.K.; Nielsen D.S.; Optimizing proto-cols for extraction of bacteriophages prior to metagenomic analyses of phage communities in the human gut. Microbiome 2015,3(1),64","journal-title":"Microbiome"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1128\/IAI.00138-16","volume":"84","author":"Ebner P.","year":"2016","unstructured":"Ebner P.; Rinker J.; Nguyen M.T.; Popella P.; Nega M.; Luqman A.; Schittek B.; Di Marco M.; Stevanovic S.; G\u00f6tz F.; Excreted cyto-plasmic proteins contribute to pathogenicity in Staphylococcus aureus. Infect Immun 2016,84(6),1672-1681","journal-title":"Infect Immun"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.3389\/fmicb.2016.01515","volume":"7","author":"G\u00f3rski A.","year":"2016","unstructured":"G\u00f3rski A.; Mi\u0119dzybrodzki R.; Weber-D\u0105browska B.; Fortuna W.; Letkiewicz S.; Rog\u00f3\u017c P.; Jo\u0144czyk-Matysiak E.; D\u0105browska K.; Majewska J.; Borysowski J.; Phage therapy: Combating infections with potential for evolving from merely a treatment for complications to targeting diseases. Front Microbiol 2016,7,1515","journal-title":"Front Microbiol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ijantimicag.2007.04.006","volume":"30","author":"Hanlon G.W.","year":"2007","unstructured":"Hanlon G.W.; Bacteriophages: an appraisal of their role in the treatment of bacterial infections. Int J Antimicrob Agents 2007,30(2),118-128","journal-title":"Int J Antimicrob Agents"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40005-020-00503-x","volume":"51","author":"Abbaszadeh F.","year":"2021","unstructured":"Abbaszadeh F.; Leylabadlo H.E.; Alinezhad F.; Feizi H.; Mobed A.; Baghbanijavid S.; Baghi H.B.; Bacteriophages: cancer diagnosis, treatment, and future prospects. J Pharm Investig 2021,51(1),23-34","journal-title":"J Pharm Investig"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"e1008318","DOI":"10.1371\/journal.ppat.1008318","volume":"16","author":"Wang D.","year":"2020","unstructured":"Wang D.; 5 challenges in understanding the role of the virome in health and disease. PLoS Pathog 2020,16(3),e1008318","journal-title":"PLoS Pathog"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.cis.2017.05.014","volume":"249","author":"Malik D.J.","year":"2017","unstructured":"Malik D.J.; Sokolov I.J.; Vinner G.K.; Mancuso F.; Cinquerrui S.; Vladisavljevic G.T.; Clokie M.R.J.; Garton N.J.; Stapley A.G.F.; Kirpichnikova A.; Formulation, stabilisation and encapsulation of bacteriophage for phage therapy. Adv Colloid Interface Sci 2017,249,100-133","journal-title":"Adv Colloid Interface Sci"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/978-1-4939-7395-8_9","author":"Merabishvili M.","year":"2018","unstructured":"Merabishvili M.; Pirnay J.P.; Vos D.D.; Guidelines to compose an ideal bacteriophage cocktail. Bacteriophage Therapy 2018,99-110","journal-title":"Bacteriophage Therapy"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.resmic.2019.06.001","volume":"170","author":"Orelle C.","year":"2019","unstructured":"Orelle C.; Mathieu K.; Jault J.M.; Multidrug ABC transporters in bacteria. Res Microbiol 2019,170(8),381-391","journal-title":"Res Microbiol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.chom.2017.06.018","volume":"22","author":"Roach D.R.","year":"2017","unstructured":"Roach D.R.; Leung C.Y.; Henry M.; Morello E.; Singh D.; Di Santo J.P.; Weitz J.S.; Debarbieux L.; Synergy between the host immune system and bacteriophage is essential for successful phage therapy against an acute respiratory pathogen. Cell Host Microbe 2017,22(1),38-47.e4","journal-title":"Cell Host Microbe"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"e0205728","DOI":"10.1371\/journal.pone.0205728","volume":"13","author":"Gonz\u00e1lez-Men\u00e9ndez E.","year":"2018","unstructured":"Gonz\u00e1lez-Men\u00e9ndez E.; Fern\u00e1ndez L.; Guti\u00e9rrez D.; Rodr\u00edguez A.; Mart\u00ednez B.; Garc\u00eda P.; Comparative analysis of different preserva-tion techniques for the storage of staphylococcus phages aimed for the industrial development of phage-based antimicrobial products. PLoS One 2018,13(10),e0205728","journal-title":"PLoS One"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"303","DOI":"10.21775\/cimb.040.303","volume":"40","author":"Malik D.J.","year":"2021","unstructured":"Malik D.J.; Bacteriophage encapsulation using spray drying for phage therapy. Curr Issues Mol Biol 2021,40(1),303-316","journal-title":"Curr Issues Mol Biol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"e0182121","DOI":"10.1371\/journal.pone.0182121","volume":"12","author":"Merabishvili M.","year":"2017","unstructured":"Merabishvili M.; Monserez R.; van Belleghem J.; Rose T.; Jennes S.; De Vos D.; Verbeken G.; Vaneechoutte M.; Pirnay J.P.; Stability of bacteriophages in burn wound care products. PLoS One 2017,12(7),e0182121","journal-title":"PLoS One"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1473-3099(18)30482-1","volume":"19","author":"Jault P.","year":"2019","unstructured":"Jault P.; Leclerc T.; Jennes S.; Pirnay J.P.; Que Y.A.; Resch G.; Rousseau A.F.; Ravat F.; Carsin H.; Le Floch R.; Schaal J.V.; Soler C.; Fevre C.; Arnaud I.; Bretaudeau L.; Gabard J.; Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): A randomised, controlled, double-blind phase 1\/2 trial. Lancet Infect Dis 2019,19(1),35-45","journal-title":"Lancet Infect Dis"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ijpharm.2017.01.060","volume":"521","author":"Leung S.S.Y.","year":"2017","unstructured":"Leung S.S.Y.; Parumasivam T.; Gao F.G.; Carter E.A.; Carrigy N.B.; Vehring R.; Finlay W.H.; Morales S.; Britton W.J.; Kutter E.; Chan H.K.; Effects of storage conditions on the stability of spray dried, inhalable bacteriophage powders. Int J Pharm 2017,521(1-2),141-149","journal-title":"Int J Pharm"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S1697-2600(14)70033-X","volume":"14","author":"Gonz\u00e1lez-Men\u00e9ndez A.","year":"2014","unstructured":"Gonz\u00e1lez-Men\u00e9ndez A.; Fern\u00e1ndez P.; Rodr\u00edguez F.; Villagr\u00e1 P.; Long-term outcomes of acceptance and commitment therapy in drug-dependent female inmates: A randomized controlled trial. Int J Clin Health Psychol 2014,14(1),18-27","journal-title":"Int J Clin Health Psychol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1016\/S1473-3099(21)00612-5","volume":"22","author":"Uyttebroek S.","year":"2022","unstructured":"Uyttebroek S.; Chen B.; Onsea J.; Ruythooren F.; Debaveye Y.; Devolder D.; Spriet I.; Depypere M.; Wagemans J.; Lavigne R.; Pirnay J.P.; Merabishvili M.; De Munter P.; Peetermans W.E.; Dupont L.; Van Gerven L.; Metsemakers W.J.; Safety and efficacy of phage therapy in difficult-to-treat infections: A systematic review. Lancet Infect Dis 2022,22(8),e208-e220","journal-title":"Lancet Infect Dis"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/978-1-4939-7395-8_20","author":"Cort\u00e9s P.","year":"2018","unstructured":"Cort\u00e9s P.; Cano-Sarabia M.; Colom J.; Otero J.; Maspoch D.; Llagostera M.; Nano\/Micro formulations for bacteriophage delivery. Bacteriophage Therapy 2018,271-283","journal-title":"Bacteriophage Therapy"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1128\/aem.56.10.3170-3173.1990","volume":"56","author":"Cornax R.","year":"1990","unstructured":"Cornax R.; Mori\u00f1igo M.A.; Paez I.G.; Mu\u00f1oz M.A.; Borrego J.J.; Application of direct plaque assay for detection and enumeration of bacteriophages of Bacteroides fragilis from contaminated-water samples. Appl Environ Microbiol 1990,56(10),3170-3173","journal-title":"Appl Environ Microbiol"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/978-1-60327-164-6_7","author":"Kropinski A.M.","year":"2009","unstructured":"Kropinski A.M.; Mazzocco A.; Waddell T.E.; Lingohr E.; Johnson R.P.; Enumeration of bacteriophages by double agar overlay plaque assay. Bacteriophages 2009,69-76","journal-title":"Bacteriophages"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"4779","DOI":"10.1128\/AEM.00295-08","volume":"74","author":"del Rio B.","year":"2008","unstructured":"del Rio B.; Mart\u00edn M.C.; Mart\u00ednez N.; Magad\u00e1n A.H.; Alvarez M.A.; Multiplex fast real-time PCR for quantitative detection and identifi-cation of cos-and pac-type Streptococcus thermophilus bacteriophages. Appl Environ Microbiol 2008,74(15),4779-4781","journal-title":"Appl Environ Microbiol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1111\/1758-2229.12991","volume":"13","author":"Guo Y.","year":"2021","unstructured":"Guo Y.; Lin J.; Wang X.; Rapid detection of temperate bacteriophage using a simple motility assay. Environ Microbiol Rep 2021,13(5),728-734","journal-title":"Environ Microbiol Rep"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"24.457595","DOI":"10.1101\/2021.08.24.457595","author":"Buchholz H.H.","year":"2021","unstructured":"Buchholz H.H.; Bola\u00f1os L.M.; Bell A.G.; Michelsen M.L.; Allen M.; Temperton B.; Genomic evidence for inter-class host transition between abundant streamlined heterotrophs by a novel and ubiquitous marine methylophage. bioRxiv 2021,24.457595","journal-title":"bioRxiv"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/IM9.0000000000000013","volume":"1","author":"Manohar P.","year":"2019","unstructured":"Manohar P.; Tamhankar A.J.; Leptihn S.; Ramesh N.; Pharmacological and immunological aspects of phage therapy. Infect Microb Dis 2019,1(2),34-42","journal-title":"Infect Microb Dis"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"11197","DOI":"10.1073\/pnas.0704624104","volume":"104","author":"Lu T.K.","year":"2007","unstructured":"Lu T.K.; Collins J.J.; Dispersing biofilms with engineered enzymatic bacteriophage. Proc Natl Acad Sci 2007,104(27),11197-11202","journal-title":"Proc Natl Acad Sci"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"5340","DOI":"10.1128\/AEM.01434-14","volume":"80","author":"Pei R.","year":"2014","unstructured":"Pei R.; Lamas-Samanamud G.R.; Inhibition of biofilm formation by T7 bacteriophages producing quorum-quenching enzymes. Appl Environ Microbiol 2014,80(17),5340-5348","journal-title":"Appl Environ Microbiol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.tim.2018.10.008","volume":"27","author":"Monteiro R.","year":"2019","unstructured":"Monteiro R.; Pires D.P.; Costa A.R.; Azeredo J.; Phage therapy: Going temperate? Trends Microbiol 2019,27(4),368-378","journal-title":"Trends Microbiol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.virol.2012.09.026","volume":"434","author":"Jacobs-Sera D.","year":"2012","unstructured":"Jacobs-Sera D.; Marinelli L.J.; Bowman C.; Broussard G.W.; Guerrero Bustamante C.; Boyle M.M.; Petrova Z.O.; Dedrick R.M.; Pope W.H.; Modlin R.L.; Hendrix R.W.; Hatfull G.F.; On the nature of mycobacteriophage diversity and host preference. Virology 2012,434(2),187-201","journal-title":"Virology"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.mimet.2008.03.005","volume":"74","author":"Knezevic P.","year":"2008","unstructured":"Knezevic P.; Petrovic O.; A colorimetric microtiter plate method for assessment of phage effect on Pseudomonas aeruginosa biofilm. J Microbiol Methods 2008,74(2-3),114-118","journal-title":"J Microbiol Methods"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1128\/AEM.02850-14","volume":"81","author":"Kamal F.","year":"2015","unstructured":"Kamal F.; Dennis J.J.; Burkholderia cepacia complex phage-antibiotic synergy (PAS): Antibiotics stimulate lytic phage activity. Appl Environ Microbiol 2015,81(3),1132-1138","journal-title":"Appl Environ Microbiol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1080\/17474124.2017.1342534","volume":"11","author":"Br\u00fcssow H.","year":"2017","unstructured":"Br\u00fcssow H.; Phage therapy for the treatment of human intestinal bacterial infections: Soon to be a reality? Expert Rev Gastroenterol Hepatol 2017,11(9),785-788","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"797","DOI":"10.2217\/fmb.12.58","volume":"7","author":"Harper D.R.","year":"2012","unstructured":"Harper D.R.; Morales S.; Bacteriophage therapy: Practicability and clinical need meet in the multidrug-resistance era. Future Microbiol 2012,7(7),797-799","journal-title":"Future Microbiol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.3389\/fimmu.2017.01783","volume":"8","author":"G\u00f3rski A.","year":"2017","unstructured":"G\u00f3rski A.; Jo\u0144czyk-Matysiak E.; \u0141usiak-Szelachowska M.; Mi\u0119dzybrodzki R.; Weber-D\u0105browska B.; Borysowski J.; The potential of phage therapy in sepsis. Front Immunol 2017,8,1783","journal-title":"Front Immunol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"e0156237","DOI":"10.1371\/journal.pone.0156237","volume":"11","author":"De Vos D.","year":"2016","unstructured":"De Vos D.; Pirnay J.P.; Bilocq F.; Jennes S.; Verbeken G.; Rose T.; Keersebilck E.; Bosmans P.; Pieters T.; Hing M.; Heuninckx W.; De Pauw F.; Soentjens P.; Merabishvili M.; Deschaght P.; Vaneechoutte M.; Bogaerts P.; Glupczynski Y.; Pot B.; van der Reijden T.J.; Dijkshoorn L.; Molecular epidemiology and clinical impact of Acinetobacter calcoaceticus-baumannii complex in a Belgian burn wound center. PLoS One 2016,11(5),e0156237","journal-title":"PLoS One"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3390\/antibiotics9070377","volume":"9","author":"Duplessis C.A.","year":"2020","unstructured":"Duplessis C.A.; Biswas B.; A review of topical phage therapy for chronically infected wounds and preparations for a randomized adaptive clinical trial evaluating topical phage therapy in chronically infected diabetic foot ulcers. Antibiotics 2020,9(7),377","journal-title":"Antibiotics"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/pathogens5010010","volume":"5","author":"Wagenlehner F.","year":"2016","unstructured":"Wagenlehner F.; Tandogdu Z.; Bartoletti R.; Cai T.; Cek M.; Kulchavenya E.; K\u00f6ves B.; Naber K.; Perepanova T.; Tenke P.; Wullt B.; Bogenhard F.; Johansen T.; The global prevalence of infections in urology study: A long-term, worldwide surveillance study on uro-logical infections. Pathogens 2016,5(1),10","journal-title":"Pathogens"},{"key":"ref=95","first-page":"60","author":"Sakandelidze V.M.","year":"1991","unstructured":"Sakandelidze V.M.; The combined use of specific phages and antibiotics in different infectious allergoses. Vrach Delo 1991(3),60-63","journal-title":"Vrach Delo"},{"key":"ref=96","first-page":"39","author":"Anpilov L.I.","year":"1984","unstructured":"Anpilov L.I.; Prokudin A.A.; Preventive effectiveness of dried polyvalent Shigella bacteriophage in organized collective farms. Voen Med Zh 1984(5),39-40","journal-title":"Voen Med Zh"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/1574-6968.12493","volume":"356","author":"Augustine J.","year":"2014","unstructured":"Augustine J.; Gopalakrishnan M.V.; Bhat S.G.; Application of \u03a6SP-1 and \u03a6SP-3 as a therapeutic strategy against Salmonella Enteritidis infection using Caenorhabditis elegans as model organism. FEMS Microbiol Lett 2014,356(1),113-117","journal-title":"FEMS Microbiol Lett"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"e02573","DOI":"10.1128\/AAC.02573-17","volume":"62","author":"Forti F.","year":"2018","unstructured":"Forti F.; Roach D.R.; Cafora M.; Pasini M.E.; Horner D.S.; Fiscarelli E.V.; Rossitto M.; Cariani L.; Briani F.; Debarbieux L.; Ghisot-ti D.; Design of a broad-range bacteriophage cocktail that reduces Pseudomonas aeruginosa biofilms and treats acute infections in two an-imal models. Antimicrob Agents Chemother 2018,62(6),e02573-e17","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jgar.2019.05.005","volume":"19","author":"Leshkasheli L.","year":"2019","unstructured":"Leshkasheli L.; Kutateladze M.; Balarjishvili N.; Bolkvadze D.; Save J.; Oechslin F.; Que Y.A.; Resch G.; Efficacy of newly isolated and highly potent bacteriophages in a mouse model of extensively drug-resistant Acinetobacter baumannii bacteraemia. J Glob Antimicrob Resist 2019,19,255-261","journal-title":"J Glob Antimicrob Resist"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"e00512","DOI":"10.1128\/IAI.00512-19","volume":"87","author":"Al-Zubidi M.","year":"2019","unstructured":"Al-Zubidi M.; Widziolek M.; Court E.K.; Gains A.F.; Smith R.E.; Ansbro K.; Alrafaie A.; Evans C.; Murdoch C.; Mesnage S.; Doug-las C.W.I.; Rawlinson A.; Stafford G.P.; Identification of novel bacteriophages with therapeutic potential that target Enterococcus faecalis. Infect Immun 2019,87(11),e00512-e00519","journal-title":"Infect Immun"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1128\/AAC.01774-15","volume":"60","author":"Nale J.Y.","year":"2016","unstructured":"Nale J.Y.; Spencer J.; Hargreaves K.R.; Buckley A.M.; Trzepi\u0144ski P.; Douce G.R.; Clokie M.R.J.; Bacteriophage combinations signifi-cantly reduce Clostridium difficile growth in vitro and proliferation in vivo. Antimicrob Agents Chemother 2016,60(2),968-981","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1046\/j.1365-4362.2002.01451.x","volume":"41","author":"Markoishvili K.","year":"2002","unstructured":"Markoishvili K.; Tsitlanadze G.; Katsarava R.; Glenn J.; Sulakvelidze A.; Sulakvelidze A.; A novel sustained-release matrix based on biodegradable poly(ester amide)s and impregnated with bacteriophages and an antibiotic shows promise in management of infected ve-nous stasis ulcers and other poorly healing wounds. Int J Dermatol 2002,41(7),453-458","journal-title":"Int J Dermatol"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"722831","DOI":"10.3389\/fmicb.2021.722831","volume":"12","author":"Senhaji-Kacha A.","year":"2021","unstructured":"Senhaji-Kacha A.; Esteban J.; Garcia-Quintanilla M.; Corrigendum: considerations for phage therapy against Mycobacterium abscessus. Front Microbiol 2021,12,722831","journal-title":"Front Microbiol"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/735413","volume":"2014","author":"Jo\u0144czyk-Matysiak E.","year":"2014","unstructured":"Jo\u0144czyk-Matysiak E.; K\u0142ak M.; Weber-D\u0105browska B.; Borysows-ki J.; G\u00f3rski A.; Possible use of bacteriophages active against Bacillus anthracis and other B. cereus group members in the face of a bioterrorism threat. BioMed Res Int 2014,2014,1-14","journal-title":"BioMed Res Int"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1073\/pnas.1714658115","volume":"115","author":"Kilcher S.","year":"2018","unstructured":"Kilcher S.; Studer P.; Muessner C.; Klumpp J.; Loessner M.J.; Cross-genus rebooting of custom-made, synthetic bacteriophage genomes in L-form bacteria. Proc Natl Acad Sci 2018,115(3),567-572","journal-title":"Proc Natl Acad Sci"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1146\/annurev-virology-092917-043544","volume":"5","author":"Lemire S.","year":"2018","unstructured":"Lemire S.; Yehl K.M.; Lu T.K.; Phage-based applications in synthetic biology. Annu Rev Virol 2018,5(1),453-476","journal-title":"Annu Rev Virol"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3390\/v10060288","volume":"10","author":"G\u00f3rski A.","year":"2018","unstructured":"G\u00f3rski A.; Mi\u0119dzybrodzki R.; \u0141obocka M.; G\u0142owacka-Rutkowska A.; Bednarek A.; Borysowski J.; Jo\u0144czyk-Matysiak E.; \u0141usiak-Szelachowska M.; Weber-D\u0105browska B.; Bagi\u0144ska N.; Letkiewicz S.; D\u0105browska K.; Scheres J.; Phage therapy: What have we learned? Viruses 2018,10(6),288","journal-title":"Viruses"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3390\/v10020064","volume":"10","author":"Pirnay J.P.","year":"2018","unstructured":"Pirnay J.P.; Verbeken G.; Ceyssens P.J.; Huys I.; De Vos D.; Ameloot C.; Fauconnier A.; The magistral phage. Viruses 2018,10(2),64","journal-title":"Viruses"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0022-5193(66)90178-0","volume":"10","author":"Cairns-Smith A.G.","year":"1966","unstructured":"Cairns-Smith A.G.; The origin of life and the nature of the primitive gene. J Theor Biol 1966,10(1),53-88","journal-title":"J Theor Biol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1128\/AAC.43.12.2925","volume":"43","author":"Bass L.","year":"1999","unstructured":"Bass L.; Liebert C.A.; Lee M.D.; Summers A.O.; White D.G.; Thayer S.G.; Maurer J.J.; Incidence and characterization of integrons, genetic elements mediating multiple-drug resistance, in avian Escherichia coli. Antimicrob Agents Chemother 1999,43(12),2925-2929","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"237","DOI":"10.12968\/jowc.2009.18.6.42801","volume":"18","author":"Rhoads D.D.","year":"2009","unstructured":"Rhoads D.D.; Wolcott R.D.; Kuskowski M.A.; Wolcott B.M.; Ward L.S.; Sulakvelidze A.; Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J Wound Care 240-2432009,18(6),237-243","journal-title":"J Wound Care"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/j.1749-4486.2009.01973.x","volume":"34","author":"Wright A.","year":"2009","unstructured":"Wright A.; Hawkins C.H.; \u00c4ngg\u00e5rd E.E.; Harper D.R.; A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol 2009,34(4),349-357","journal-title":"Clin Otolaryngol"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.2217\/fmb-2020-0082","volume":"15","author":"G\u00f3rski A.","year":"2020","unstructured":"G\u00f3rski A.; Mi\u0119dzybrodzki R.; \u017baczek M.; Borysowski J.; Phages in the fight against COVID-19? Future Microbiol 2020,15(12),1095-1100","journal-title":"Future Microbiol"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ebiom.2015.12.023","volume":"4","author":"Sarker S.A.","year":"2016","unstructured":"Sarker S.A.; Sultana S.; Reuteler G.; Moine D.; Descombes P.; Charton F.; Bourdin G.; McCallin S.; Ngom-Bru C.; Neville T.; Akter M.; Huq S.; Qadri F.; Talukdar K.; Kassam M.; Delley M.; Loiseau C.; Deng Y.; El Aidy S.; Berger B.; Br\u00fcssow H.; Oral phage ther-apy of acute bacterial diarrhea with two coliphage preparations: a randomized trial in children from Bangladesh. EBioMedicine 2016,4,124-137","journal-title":"EBioMedicine"},{"key":"ref=115","first-page":"66","volume":"4","author":"Rose T.","year":"2014","unstructured":"Rose T.; Verbeken G.; Vos D.D.; Merabishvili M.; Vaneechoutte M.; Lavigne R.; Jennes S.; Zizi M.; Pirnay J.P.; Experimental phage therapy of burn wound infection: Difficult first steps. Int J Burns Trauma 2014,4(2),66-73","journal-title":"Int J Burns Trauma"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"fnv242","DOI":"10.1093\/femsle\/fnv242","volume":"363","author":"Speck P.","year":"2016","unstructured":"Speck P.; Smithyman A.; Safety and efficacy of phage therapy via the intravenous route. FEMS Microbiol Lett 2016,363(3),fnv242","journal-title":"FEMS Microbiol Lett"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3389\/fmicb.2016.00465","volume":"7","author":"Sybesma W.","year":"2016","unstructured":"Sybesma W.; Zbinden R.; Chanishvili N.; Kutateladze M.; Chkhotua A.; Ujmajuridze A.; Mehnert U.; Kessler T.M.; Bacteriophages as potential treatment for urinary tract infections. Front Microbiol 2016,7,465","journal-title":"Front Microbiol"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"e1004984","DOI":"10.1371\/journal.ppat.1004984","volume":"11","author":"Nguyen M.T.","year":"2015","unstructured":"Nguyen M.T.; Kraft B.; Yu W.; Demicrioglu D.D.; Hertlein T.; Burian M.; Schmaler M.; Boller K.; Bekeredjian-Ding I.; Ohlsen K.; Schittek B.; G\u00f6tz F.; The \u03bdSa\u03b1 specific lipoprotein like cluster (lpl) of S. aureus USA300 contributes to immune stimulation and invasion in human cells. PLoS Pathog 2015,11(6),e1004984","journal-title":"PLoS Pathog"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3201\/eid1903.121156","volume":"19","author":"Dutta D.","year":"2013","unstructured":"Dutta D.; Chowdhury G.; Pazhani G.P.; Guin S.; Dutta S.; Ghosh S.; Rajendran K.; Nandy R.K.; Mukhopadhyay A.K.; Bhattacharya M.K.; Mitra U.; Takeda Y.; Nair G.B.; Ramamurthy T.; Vibrio cholerae non-O1, non-O139 serogroups and cholera-like diarrhea, Kolka-ta, India. Emerg Infect Dis 2013,19(3),464-467","journal-title":"Emerg Infect Dis"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"e1002120","DOI":"10.1371\/journal.pmed.1002120","volume":"13","author":"Ali M.","year":"2016","unstructured":"Ali M.; Debes A.K.; Luquero F.J.; Kim D.R.; Park J.Y.; Digilio L.; Manna B.; Kanungo S.; Dutta S.; Sur D.; Bhattacharya S.K.; Sack D.A.; Potential for controlling cholera using a ring vaccination strategy: Re-analysis of data from a cluster-randomized clinical trial. PLoS Med 2016,13(9),e1002120","journal-title":"PLoS Med"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"94","DOI":"10.4103\/jgid.jgid_42_19","volume":"12","author":"Chakrabarti A.","year":"2020","unstructured":"Chakrabarti A.; Biswas A.; Tewari D.; Mondal P.; Dutta S.; Phage types of Vibrio cholerae 01 biotype ELtor strains isolated from India during 2012-2017. J Glob Infect Dis 2020,12(2),94-100","journal-title":"J Glob Infect Dis"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.3389\/fimmu.2020.01755","volume":"11","author":"Bekeredjian-Ding I.","year":"2020","unstructured":"Bekeredjian-Ding I.; Challenges for clinical development of vaccines for prevention of hospital-acquired bacterial infections. Front Immunol 2020,11,1755","journal-title":"Front Immunol"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1093\/ps\/81.4.437","volume":"81","author":"Huff W.E.","year":"2002","unstructured":"Huff W.E.; Huff G.R.; Rath N.C.; Balog J.M.; Xie H.; Moore P.A.; Donoghue A.M.; Prevention of Escherichia coli respiratory infec-tion in broiler chickens with bacteriophage (SPR02). Poult Sci 2002,81(4),437-441","journal-title":"Poult Sci"}],"container-title":["Current Pharmaceutical Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389201024666221207114047","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/211687\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389201024666221207114047","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T07:06:09Z","timestamp":1690182369000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/211687\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":123,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389201024666221207114047","relation":{},"ISSN":["1389-2010"],"issn-type":[{"value":"1389-2010","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-05-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-23","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}